Approval Briefs: Zohydro ER, Vyvanse For Binge Eating, Another Imbruvica Claim, Alcon Gains New Allergy Eye Drop

Reformulated opioid still doesn’t have abuse deterrence claim; Shire gains another indication for Vyvanse, this time in binge-eating; Imbruvica becomes the first drug approved for Waldenstrom’s macroglobulinemia; and, Alcon garners approval for once-daily eye drop.